auto/allografting in T-PLL

A prospective observational audit on auto and allografting in T-PLL to generate scientifically sound knowledge on HSCT in this orphan disease.

Recent retrospective analysis of the Chronic Lymphocytic Leukemia Subcommittee of the Chronic Leukemia Working Party has shown that autologous transplantation may in some cases delay progression of disease while allogeneic transplantation may provide in some cases effective control of disease. However, more formal proof of concept of using hematopoietic transplantation for treatment of T-PLL is lacking.

Ethical approval:
The EBMT decided that in general for this observational audit, no ethical approval is necessary, but this could differ per centre. Please contact your EC in case of any doubts.

Apart from MED-B forms no additional data are collected. Therefore the usual MED-B consent procedure should be sufficient.

If a patient consent form should be collected for this observational audit please could you collect and file these forms on every consecutive patient you will include in this audit at your centre.

Word forms are available on request from the data office in Leiden.

Background and Outline
EBMT/ERIC frame of orientation (in review)
Letter of Invitation
Centre registration Form
Patient registration Form
CLL MED-B form / autologous or allogeneic MED-B	CLL auto allo
Patient Consent Form	eng

For further information please contact :

EBMT Clinical Trials and Study Office - Leiden
Department of Medical Statistics & Bioinformatics
Postzone S-05-P LUMC
PO Box 9600 2300 RC
Leiden
The Netherlands

Email: clwpebmt@lumc.nl

Tel: +31-71-526 9724
Fax:+49-711-4900-8723